Estimation of Public Health Impact with Use of Nirsevimab During the 2024-2025 RSV Season in the USA: a Modeling Study.
Saved in:
| Title: | Estimation of Public Health Impact with Use of Nirsevimab During the 2024-2025 RSV Season in the USA: a Modeling Study. |
|---|---|
| Authors: | Yarnoff B; Evidera Inc., Wilmington, NC, USA. benjamin.yarnoff@thermofisher.com., Neary MP; Sanofi, Morristown, NJ, USA., Gabriel V; Sanofi, Morristown, NJ, USA., Ghemmouri M; Sanofi, Lyon, France., Hodges EN; Sanofi, Morristown, NJ, USA., Tribaldos M; Sanofi, Morristown, NJ, USA., Geurtsen J; Sanofi, Amsterdam, The Netherlands., Chit A; Sanofi, Morristown, NJ, USA.; Lesie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada., Beuvelet M; Sanofi, Lyon, France., Soudani S; Sanofi, Lyon, France., Musci R; Evidera Inc., Wilmington, NC, USA., Krilov LR; Pediatric Infectious Disease Consultant, Woodbury, NY, USA. |
| Source: | Pulmonary therapy [Pulm Ther] 2026 Jun; Vol. 12 (2), pp. 707-720. Date of Electronic Publication: 2026 Feb 26. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 101687144 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2364-1746 (Electronic) Linking ISSN: 23641754 NLM ISO Abbreviation: Pulm Ther Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2364-1746 |
|---|---|
| DOI: | 10.1007/s41030-026-00348-z |
